For patients with unresectable colorectal cancer liver metastases and right-sided RAS or BRAF mutations, FOLFOXIRI plus bevacizumab vs. FOLFOX/FOLFIRI plus bevacizumab significantly increased PFS, according toASCO Annual Meeting results.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
